Samsung units invests in Arbor Biotechnologies

South Korea-based Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, today announced an equity investment in Arbor Biotechnologies, a US clinical stage biotechnology company discovering and developing the next generation of in vivo genetic medicines.

The investment, the value of which was not disclosed, strengthens Samsung’s commitment to enabling advanced biopharmaceutical technologies such as genetic medicines, and supports Arbor’s mission to translate cutting-edge gene editing technologies into therapeutics that offer life-changing potential for patients with serious diseases with high unmet medical need.

“Arbor Biotechnologies’ represents a best-in-class gene editing company with the potential to transform how genetic diseases are treated,” said Yun Cheol Kim, vice president of research and early development at Samsung Bioepis, adding; “Our investment reflects our commitment to advancing breakthrough technologies that can bring meaningful impact to patients worldwide.”